Rayaldee Available for Treating Secondary Hyperparathyroidism

Rayaldee was approved in June for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 CKD
Rayaldee was approved in June for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 CKD

Opko Health announced that Rayaldee (calcifediol) extended-release capsules will be available in pharmacies as early as Wednesday, November 30. 

Rayaldee was initially approved by the Food and Drug Administration (FDA) in June 2016 for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels <30ng/mL. Its patented formulation is designed to raise prohormone concentrations to targeted levels and to decrease elevated intact parathyroid hormone (iPTH). 

Related Articles

Calcifediol (25-hydroxyvitamin D3) is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis.

Rayaldee is available as 30mcg strength extended-release capsules in 30- and 60-count bottles.

For more information call (844) 729-2539 or visit Rayaldee.com.

Loading links....